Myriad Genetics Management
Management criteria checks 2/4
Myriad Genetics' CEO is Paul Diaz, appointed in Aug 2020, has a tenure of 4.42 years. total yearly compensation is $12.11M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $5.72M. The average tenure of the management team and the board of directors is 2.6 years and 4.5 years respectively.
Key information
Paul Diaz
Chief executive officer
US$12.1m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 4.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.6yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Jan 08
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 13Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?
Nov 02Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge
Nov 02Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?
Sep 20Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking
Aug 30Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Jul 17Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?
Jun 05Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 11Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 09Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Mar 28An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued
Feb 02Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Jan 31Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price
Dec 18Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?
Aug 07Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Apr 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$116m |
| Jun 30 2024 | n/a | n/a | -US$155m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$12m | US$1m | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$274m |
| Jun 30 2023 | n/a | n/a | -US$248m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$11m | US$1m | -US$112m |
| Sep 30 2022 | n/a | n/a | -US$77m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$13m | US$1m | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$57m |
| Jun 30 2021 | n/a | n/a | -US$97m |
| Mar 31 2021 | n/a | n/a | -US$148m |
| Dec 31 2020 | US$16m | US$383k | -US$224m |
Compensation vs Market: Paul's total compensation ($USD12.11M) is above average for companies of similar size in the US market ($USD5.34M).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
CEO
Paul Diaz (62 yo)
4.4yrs
Tenure
US$12,108,359
Compensation
Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$12.11m | 0.44% $ 5.7m | |
| Chief Operating Officer | 1.1yrs | US$5.02m | 0.034% $ 438.1k | |
| Chief Scientific Officer | 3yrs | US$2.23m | 0.12% $ 1.5m | |
| Chief Commercial Officer | 7.4yrs | US$2.88m | 0.32% $ 4.1m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Principal Accounting Officer | 2.6yrs | no data | 0.048% $ 618.6k | |
| Chief Technology Officer | 3.9yrs | US$1.64m | 0.14% $ 1.9m | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Senior VP & Chief Marketing Officer | 2.1yrs | no data | no data | |
| Chief People Officer | 1.8yrs | no data | 0.0031% $ 40.9k | |
| Executive Vice President of Strategy & Innovation | 3.7yrs | no data | no data |
2.6yrs
Average Tenure
51yo
Average Age
Experienced Management: MYGN's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$12.11m | 0.44% $ 5.7m | |
| Independent Director | 2.3yrs | US$258.48k | 0.027% $ 349.7k | |
| Independent Director | 5.3yrs | US$447.99k | 0.073% $ 953.1k | |
| Independent Director | 4.5yrs | US$433.49k | 0.077% $ 1.0m | |
| Independent Director | 5.3yrs | US$443.49k | 0.029% $ 383.8k | |
| Independent Director | 14.6yrs | US$443.49k | 0.12% $ 1.5m | |
| Director | less than a year | no data | no data | |
| Independent Chair of the Board | 15.3yrs | US$563.49k | 0.16% $ 2.1m | |
| Independent Director | 4.3yrs | US$433.49k | 0.068% $ 882.2k |
4.5yrs
Average Tenure
63yo
Average Age
Experienced Board: MYGN's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 00:15 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Myriad Genetics, Inc. is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |